Ropinirol en el tratamiento de la enfermedad de Parkinson: actualización

Vivancos-Matellano, F

doi:10.33588/rn.4209.2005737

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[35] In PD patients with exercise fluctuations, ropinirole, as an adjunct to L-DA, has been proven in early trials to improve the symptoms of PD. [36] It has been reported that the use of ropinirole as an adjuvant therapy can also significantly reduce the dosage of L-DA. [37] UPDRS score is a scale that evaluates the severity of PD.…”

Section: Discussionmentioning

confidence: 99%

“…It has negligible affinity for a wide range of central non-dopaminergic receptors, including a and β adrenergic receptors, serotonin receptor type 1, serotonin receptor type 2, benzodiazepines, and γ-GABA receptor [35] . In PD patients with exercise fluctuations, ropinirole, as an adjunct to L-DA, has been proven in early trials to improve the symptoms of PD [36] . It has been reported that the use of ropinirole as an adjuvant therapy can also significantly reduce the dosage of L-DA [37] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The effect and safety of ropinirole in the treatment of Parkinson disease

Zhu

Chen²

2021

Medicine

View full text Add to dashboard Cite

Background:It is necessary to conduct a meta-analysis of the clinical randomized controlled trials (RCTs) on ropinirole in the treatment of Parkinson disease (PD), to explore the effects and safety of ropinirole, and to provide a theoretical basis for clinically safe and rational drug use.Methods:RCTs on the effectiveness and safety of ropinirole in the treatment of PD were searched. We searched Dutch medical literature database, Pubmed, Cochrane Library, China National Knowledge Infrastructure, Wanfang Knowledge Service Platform up to December 15, 2020. The Cochrane risk bias assessment tool was used to evaluate the quality of the included literature, and the RevMan5.3 software was used for meta-analysis.Results:A total of 12 RCTs with 3341 patients were included. The changes of Parkinson Disease Rating Scale Part II score (mean difference = –2.23, 95% confidence interval [CI] –2.82 to –1.64) and Parkinson Disease Rating Scale Part III scores (mean difference = –4.93, 95%CI –5.25 to –4.61) in the ropinirole group was significantly lower than that in the control group. The incidence of dizziness (odd risk [OR] = 1.85, 95%CI 1.50–2.28), nausea (OR = 2.17, 95%CI 1.81–2.59), vomiting (OR = 2.73, 95%CI 1.47–5.09), and lethargy (OR = 2.19, 95%CI 1.39–3.44) in the ropinirole group was significantly higher than that in the control group (all P < .05), and there were no significant differences in the incidence of headache (OR = 1.14, 95%CI 0.79–1.65) and insomnia (OR = 1.06, 95%CI 0.72–1.55) were found between 2 groups (all P > .05).Conclusions:Ropinirole can help improve the ability of daily living and exercise function of PD patients, but it will increase the incidence of related adverse reactions, which needs to be further confirmed by subsequent large-scale, high-quality RCTs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%